CORONA, Calif., May 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that, under a supply agreement with GlaxoSmithKline (GSK), Watson has initiated shipments of bupropion hydrochloride sustained-release tablets, in the 150mg strength. The product is the generic version of GlaxoSmithKline’s Zyban(R), which is indicated for smoking cessation. For the 12-months ending March 2004, Zyban(R) 150mg had sales of approximately $60 million, according to IMS Health data.
Under a previously announced settlement with GSK, Watson received rights in the United States (U.S.) market to distribute 100mg and 150mg bupropion hydrochloride sustained-release tablets, manufactured by a GSK subsidiary, on a per strength basis, once a third party launches a fully substitutable generic equivalent of the relevant strength of these products in the U.S. market. Watson launched generic versions of Wellbutrin SR(R) in the 100mg strength in January 2004 and the 150mg strength in March 2004. GSK will receive a share of the profits from Watson’s sales of generic bupropion hydrochloride sustained-release tablets in the U.S. market. Terms of the agreement were not disclosed.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceutical’s Web site at http://www.watsonpharm.com/.
Forward-Looking Statement
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson’s current expectations depending upon a number of factors affecting Watson’s business. These factors include, among others, the impact of competitive products and pricing, market acceptance of and demand for Watson’s products, and risks and uncertainties detailed in Watson’s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson’s Annual Report on Form 10-K for the year ended December 31, 2003, Quarterly Report on Form 10-Q for the quarter ended March 31, 2004.
Wellbutrin SR(R) and Zyban(R) are registered trademarks of the GlaxoSmithKline group of companies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.
CONTACT: investors, Patty Eisenhaur, +1-909-493-5611, or media, ChrisEso, +1-909-493-4013, both Watson Pharmaceuticals, Inc.
Web site: http://www.watsonpharm.com/
